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Cells Lacking the Fumarase Tumor Suppressor Are Protected from
Apoptosis through a Hypoxia-Inducible Factor-Independent,
AMPK-Dependent Mechanism
Chiara Bardella,a,b* Martina Olivero,a,b Annalisa Lorenzato,a,b Massimo Geuna,c Julie Adam,d Linda O’Flaherty,d Pierre Rustin,e,f
Ian Tomlinson,g Patrick J. Pollard,d and Maria Flavia Di Renzoa,b
Department of Oncological Sciences, University of Torino, School of Medicine, Turin, Italya; Laboratory of Cancer Genetics, Institute for Cancer Research at Candiolo (IRCC),
Candiolo, Turin, Italyb; Laboratory of Immunopathology, Department of Pathology, ASO Ordine Mauriziano, Turin, Italyc; Henry Wellcome Building for Molecular
Physiology, University of Oxford, Oxford, United Kingdomd; INSERM, U676, Paris, Francee; Université Paris 7, Faculté de Médecine Denis Diderot, IFR02, Paris, Francef; and
Molecular and Population Genetics Laboratory and Oxford NIHR Comprehensive Biomedical Research Centre, Wellcome Trust Centre for Human Genetics, University of
Oxford, Oxford, United Kingdomg
Loss-of-functionmutations of the tumor suppressor gene encoding fumarase (FH) occur in individuals with hereditary leiomyo-
matosis and renal cell cancer syndrome (HLRCC). We found that loss of FH activity conferred protection from apoptosis in nor-
mal human renal cells and fibroblasts. In FH-defective cells, both hypoxia-inducible factor 1 (HIF-1) and HIF-2 accumu-
lated, but they were not required for apoptosis protection. Conversely, AMP-activated protein kinase (AMPK) was activated and
required, as evidenced by the finding that FH inactivation failed to protect AMPK-null mouse embryo fibroblasts (MEFs) and
AMPK-depleted human renal cells. Activated AMPKwas detected in renal cysts, which occur in mice with kidney-targeted dele-
tion of Fh1 and in kidney cancers of HLRCC patients. In Fh1-null MEFs, AMPK activation was sustained by fumarate accumula-
tion and not by defective energy metabolism. Addition of fumarate and succinate to kidney cells led to extracellular signal-regu-
lated kinase 1/2 (ERK1/2) and AMPK activation, probably through a receptor-mediated mechanism. These findings reveal a new
mechanism of tumorigenesis due to FH loss and an unexpected pro-oncogenic role for AMPK that is important in considering
AMPK reactivation as a therapeutic strategy against cancer.
The fumarase gene (FH; fumarate hydratase gene) encodes ahighly conserved protein (EC 4.2.1.2) which in mitochondria
catalyzes the conversion of fumarate to malate as part of the tri-
carboxylic acid cycle (TCA or Krebs cycle). Germ line mutations
in FH are associatedwith two distinct diseases. In the homozygous
or compound heterozygous state, biallelic FHmutations cause an
autosomal recessive disease, the fumarase deficiency syndrome
(also known as fumaric aciduria; OMIM accession no. 606812),
characterized by severe impairment in the development of the
central nervous system (CNS) (2). Heterozygous germ line muta-
tions predispose individuals tomultiple smoothmuscle tumors of
the skin and uterus (multiple cutaneous and uterine leiomyomatosis
[MCUL]; OMIM accession no. 150800) and to an increased risk of
papillary renal carcinoma and leiomyosarcoma (hereditary leiomyo-
matosis and renal cell cancer syndrome [HLRCC]; OMIM accession
no. 605839) (56). The high frequency of inactivation of the second
allele and loss of enzymatic activity in tumor cells indicate thatFH is a
tumor suppressor gene (56).
Loss of FH activity triggers pseudohypoxic signaling (14). Ac-
cumulation of fumarate and succinate results in the inhibition of
the prolyl-hydroxylases (PHDs) (42, 51), which physiologically
hydroxylate the HIF- subunits of the hypoxia-inducible tran-
scription factor (HIF) when oxygen is available (8). HIF is a het-
erodimer composed of the labile HIF- and stable HIF-/ARNT
(aryl hydrocarbon receptor nuclear translocator) subunits (52),
which form a transcriptionally active complex in the nucleus. The
best-known function of HIF is to promote adaptation of cells to
hypoxia (37). In leiomyomas and renal tumors of HLRCC pa-
tients, high levels of intracellular fumarate accumulate, HIF-
subunits are stabilized, and HIF target genes are transcribed in
ambient normoxia, mimicking hypoxic conditions (pseudohy-
poxia) (23, 42). There is strong evidence to suggest that fumarate-
mediated inhibition of PHD activity and subsequent HIF accu-
mulation and activation are direct consequences of FH loss and
the cause of the observed pseudohypoxia (19, 39). Further evi-
dence has come from the conditional inactivation ofmouse Fh1 in
the kidney, which leads to the development of multiple clonal
renal cysts that overexpress Hif-1, Hif-2, and Hif target genes
such as Glut1 and Vegf (44). These and other HIF target genes
promote the glycolytic and angiogenic shifts that favor tumor pro-
gression. However, although several studies have demonstrated
upregulation of HIF in FH-associated neoplasia, this does not
prove that HIF accumulation is the causative oncogenic mecha-
nism.
How somatic cells survive with a Krebs cycle defect has been
explained, although a loss of FH activity is lethal for human devel-
oping neurons carrying homozygous germ line mutations in the
FH gene (2). Indeed, it has been proposed that somatic cells with
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FH loss surmount energetic impairment by becoming glucose ad-
dicted (55, 58) or using glutamine as a major source of energy (7).
More recently, it was shown that the glutamine uptake in Fh1-
deficient cells enables the use of accumulated TCA cycle metabo-
lites and permits partial mitochondrial production of NADH,
given that biosynthesis and degradation of heme are activated
(11). However, this can explain how cells tolerate the Krebs cycle
defect but not how they overcome the apoptotic signaling trig-
gered by the stresses that cancer cells experience during the course
of tumorigenesis (35). Here we show not only that FH-defective
cells can survive but also that they exhibit increased resistance to
apoptosis induced by different stimuli. Furthermore, we demon-
strate that apoptosis protection is mediated predominantly by the
activation of the AMP-activated protein kinase (AMPK).
MATERIALS AND METHODS
Chemicals, antibodies, and cell lines. Cisplatin (CDDP) was obtained
from Bristol-Myers Squibb (Rocky Hill, NJ). Staurosporine, AICAR
(5-aminoimidazole-4-carboxamide-1--4-ribofuranoside), N-acetyl-
L-cysteine, sodium pyruvate, sodium oxamate, succinate, diethyl suc-
cinate, and monoethyl fumarate were obtained from Sigma (Stein-
heim, Germany). Metformin was obtained from MP Biomedicals
(Illkirsch, France). A-769662 was obtained from Tocris Bioscience
(Bristol, United Kingdom), and cobalt chloride was purchased from
Fluka BioChemika (Buchs, Switzerland). Rabbit polyclonal anti-FH
antibody was obtained fromNordic Immunological Laboratories (Til-
burg, The Netherlands). Anti-human and -mouse HIF-1 and anti-
HIF-2 polyclonal antibodies were obtained from Novus Biologicals
(Littleton, CO). The anti-glyceraldehyde-3-phosphate dehydrogenase
(anti-GAPDH) mouse monoclonal antibody (MAb) 6C5 was obtained
from Ambion (Foster City, CA). Anti-human vinculin MAb and anti-
human tubulin MAb were obtained from Sigma-Aldrich. Anti-BAD,
anti-phosphorylated protein kinase A (anti-P-PKA) (Thr197), anti-
PKA, anti-P-p70S6K (Thr421/Ser424), anti-p70S6K, anti-P-p38 mito-
gen-activated protein kinase (MAPK) (Thr180/Tyr182), anti-p38
MAPK, anti-P-AKT (Ser473), anti-AKT, anti-P-AMPK (Thr172), an-
ti-AMPK, anti-MCL-1, anti-BCL-XL, anti-BMF, anti-BAX, anti-
BCL-2, anti-P-BCL-2 (Ser70), anti-P-Erk1/2 (Thr202/Tyr204),
anti-Erk1/2, and anti-P-ACC (Ser 79) rabbit polyclonal antibodies,
anti-acetyl coenzyme A carboxylase (anti-ACC) rabbit monoclonal
antibody, and anti-P-BAD (Ser112) mouse monoclonal antibody were
all obtained from Cell Signaling Technology (Beverly, MA). Anti-V5
antibody was obtained from Invitrogen (Eugene, OR). FH-negative
fibroblasts were derived from skin biopsy specimens from a patient
suffering from fumaric aciduria and homozygous for a missense mu-
tation (2). Control fibroblasts were propagated from a skin biopsy
specimen from a healthy individual. Renal proximal tubule epithelial
cells (RPTEC), HK-2 cells, and Hepa-1c1c7 cells and their mutant
derivative c4 and vT{2} clones were purchased from the American
Type Culture Collection (Manassas, VA) and grown as suggested by
the provider. Simian virus 40 (SV40)-immortalized AMPK 1/2
double-knockout mouse embryo fibroblasts (MEFs) and relevant con-
trol SV40-immortalized mouse fibroblasts were obtained from Benoit
Viollet (29). Immortalized Fh1-deficient MEFs were generated and
propagated as described elsewhere (39). To investigate the effects of
low and high levels of glucose supplementation of the culture medium,
Dulbecco’s modified Eagle’s medium (DMEM) without glucose was
supplemented with D-()-glucose from Sigma (Sigma-Aldrich,
France).
Human andmurine tissues. FHmutant type II papillary renal cancers
from paraffin-embedded sections were collected with full ethical ap-
proval, in collaborationwith IanTomlinson (Oxfordshire ResearchEthics
Committee [REC] B approval 05/Q1605/66 [Molecular Analyses of Ar-
chival Tumors for Human Tissues]). FH-deficient renal cysts and cells
were derived from FH mutant mice. All procedures were carried out in
accordance with HomeOffice UK regulations and the Animals (Scientific
Procedures) Act 1986. Fh1-deficient mice have been described elsewhere
(44).
Cell transduction with lentiviral vectors (LV).An FH-specific short
hairpin RNA (shRNA) sequence (forward sequence, 5=-GGAAUUUA
GUGGUUAUGUU-3=) was cloned into the pSUPER vector. Lentiviral
shRNAs were generated by subcloning the H1-RNA-promoter-shRNA
cassette from pSUPER into EcoRI-HindIII sites of the vector pCCL.sin.
PPT.hPGK.GFP.Wpre.
As a control, cells were also transduced with a scrambled shRNA (for-
ward sequence, 5=-AGUCUACAUGCUCACACUU-3=) sequence cloned
into the vector pCCL.sin.PPT.hPGK.GFP.Wpre, under the control of the
H1-RNA-promoter sequence. For FH rescue, an RNA interference-resis-
tant FH cDNA was obtained by insertion of 8 different silent mutations,
specific for the shRNA used, into the FH cDNA sequence. All mutations
were introduced using a PCR-based technique as described elsewhere
(34). Briefly, human FH cDNA, previously subcloned as a BamHI-SalI
fragment into the transfer vector pRRL.sin.PPT.hCMV.pre, was amplified
by a PCR protocol including two different courses of amplification. Sub-
sequently, the FH mutant cDNA cassette, subcloned into the pDRIVE
vector, was cloned into the lentiviral pRRL.sin.PPT.hCMV.hFH.pre
transfer vector as an XbaI-PstI fragment. The PCR primer set used to
introduce the silent mutations into the FH cDNA and the PCR amplifica-
tion conditions used are available upon request. The following HIF-1-
specific shRNAs were obtained from the Open Biosystem TRC lentiviral
shRNA library: RHS3979-9572497 and RHS3979-9572499. The following
AMPK-1- and -2-specific shRNAs were obtained from the Sigma-Al-
drich TRC lentiviral shRNA library: SHCLNG-NM_006251 (5 clones)
and SHCLNG-NM_006252 (5 clones). The pLL3.7 lentiviral vectors con-
taining either BAD-specific or control shRNAswere kindly provided byG.
Kulik (Department of Cancer Biology, Wake Forest University School of
Medicine, Winston-Salem, NC). Vector stocks were produced by tran-
sient transfection of 293T cells. Serial dilutions of freshly harvested con-
ditioned medium were used to infect 105 cells in a six-well plate, in the
presence of Polybrene (8g/ml). The viral p24 antigen concentration was
measured by an HIV-1 p24 core profile enzyme-linked immunosorbent
assay (ELISA; NEN Life Science Products) to determine the number of
infective particles before transduction and to demonstrate that trans-
duced cells did not produce viral particles after transduction.
Measurement ofROSproduction.Thefluorogenic dyeMitoSOXRed
(Molecular Probes, Invitrogen Detection Technologies), a mitochondrial
superoxide indicator, was used to detect reactive oxygen species (ROS) in
the mitochondria of live cells, following the instructions of the manufac-
turer. Briefly, 3 105 HK-2 cells were plated in 6-well plates, and after 24
h, they were either left untreated or treated with hydrogen peroxide at the
indicated concentration for 2 h and then incubatedwith 0.5MMitoSOX
solution for 20 min at 37°C, protected from light. After washing with
phosphate-buffered saline (PBS), cells were harvested with trypsin, resus-
pended in a suitable buffer, and analyzed with a flow cytometer.
Flow cytometry analysis of apoptosis induction.Apoptosis wasmea-
sured by staining with allophycocyanin (APC)-conjugated annexin V
(Bender MedSystems, Burlingame, CA) and propidium iodide (Invitro-
gen, Eugene, OR), which allow detection of the phosphatidylserine (PS)
exposure on the cell surface and the loss of plasma membrane integrity,
respectively. Cell viability was measured as the percentage of propidium
iodide-negative cells. To evaluate the effects of antioxidants and a lactate
dehydrogenase (LDH) inhibitor on apoptosis induction, cells were
treated with N-acetylcysteine, sodium pyruvate, or sodium oxamate to-
gether with cisplatin at the indicated concentrations. Caspase activation
was determined with anti-active caspase-3 (BD PharMingen, San Diego,
CA) as the primary antibody and a phycoerythrin (PE)-conjugated goat
anti-rabbit antibody (BD PharMingen, San Diego, CA) as the secondary
antibody. Samples were analyzed on a FACSCalibur flow cytometer (Bec-
Bardella et al.
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ton, Dickinson, San Diego, CA). Data acquisition was performed using
CellQuest software (Becton, Dickinson, San Diego, CA).
Quantitative reverse transcription-PCR. Total RNA was extracted
and purified using an RNA purification reagent (Promega, Madison, WI)
following the manufacturer’s instructions. RNAs were then quantified
and inspected by Bioanalyzer (Agilent Technologies, Waldbrom, Ger-
many) analysis. cDNAwas synthesized from 1g RNA by use ofMoloney
murine leukemia virus reverse transcriptase H [MMLV-RT(H)] en-
zyme (Promega, Madison, WI). Quantitative real-time PCR was done on
an MyiQ thermal cycler (Bio-Rad, Hercules, CA); all quantitative PCR
mixtures contained 40 ng retrotranscribed RNA, 1 SYBR green PCR
master mix (2 stock; Applera, Foster City, CA), and 300 M (each)
target-specific primers. Each target gene’s expression was evaluated using
a relative quantification approach (2CT method), with cyclophilin A
(PPIA; GenBank accession no. NM_021130) as an internal reference.
Primer sets and PCR cycling conditions are available upon request.
Protein extraction and Western blot analysis. For nuclear protein
analysis, cells were incubated at 4°C for 10 min with 1 ml of buffer A,
containing 10 mM HEPES, pH 7.9, 10 mM KCl, 10 mM EDTA, 1 mM
dithiothreitol (DTT), 0.5% NP-40, and phosphatase and protease inhib-
itors (2mM sodium orthovanadate, 1g/ml leupeptin, 1Mpepstatin, 1
mM phenylmethylsulfonyl fluoride, 100 g/ml soybean trypsin inhibi-
tor). Cell extracts were then centrifuged at 15,000 g for 3 min, and the
supernatant (cytosolic) fractionwas collected. The pellet was resuspended
in 150 l of buffer B (20 mMHEPES, pH 7.9; 0.4 M NaCl; 1 mM EDTA;
50% glycerol; 1 mM DTT; and the phosphatase and protease inhibitors
described above) and incubated on a rocking platform at 200 rpm for 2 h
at 4°C. After centrifugation at 15,000 g for 5 min, the supernatant was
collected as the nuclear fraction. For PAGE gels, SDS-containing buffer
was added to the fractions. Total protein extraction was performed by
directly incubating cells in SDS-containing lysis buffer at 95°C for 5 min.
Proteins were separated by PAGE and transferred to nitrocellulose sheets.
Equal amounts of proteins (100 g) were loaded in each lane. Blots were
probed and, when necessary, reprobed with different antibodies as indi-
cated in Results. Bound antibodies were detected using the appropriate
peroxidase-conjugated secondary antibody and revealed by enhanced
chemiluminescence (Pierce, Rockford, IL).
Quantitative phosphoprotein assays.Phosphorylationof kinases and
kinase substrates was measured using a Bio-Plex phosphoprotein assay
(Bioclarma, Turin, Italy) according to the manufacturer’s protocol. Ly-
sates were prepared, and phosphorylated proteins were detected with a
Bio-Rad phosphoprotein immunoassay kit, using a Bio-Plex 100 system
and workstation according to the manufacturer’s protocol. Data acquisi-
tion and analysis were done using Bio-Plex Manager software, version
4.1.1, according to the manufacturer’s instructions. In the assay, antibod-
ies to the following phosphorylated proteins were used: P-p90RSK
(Thr359, Ser363), P-c-Jun (Ser63), phosphorylated glycogen synthase ki-
nase 3a/b (P-GSK-3a/b) (Ser9, Ser21), P-ATF-2 (Thr71), P-MEK1
(Ser217, Ser221), phosphorylated extracellular signal-regulated kinase 1/2
(P-ERK1/2) (Thr202, Tyr204, Thr185, Tyr187), and phosphorylated Jun
N-terminal kinase (P-JNK) (Thr183, Tyr185). Protein phosphorylation
was investigated further using Western blot analysis with the antibodies
listed above. AMPK phosphorylation was quantified using a PathScan
phospho-AMPK ELISA kit (Cell Signaling Technology, Beverly, MA)
following the manufacturer’s instructions.
Measurement of FH enzymatic activity. FH enzyme measurement
was performed on HK-2 cell pellets. Cells/organelles were disrupted by
freeze-thawing. Fumarase activity was measured spectrophotometrically
according to standard procedures. Briefly, the assaymonitors the increase
in absorbance at 250 nm due to conversion of malate to fumarate in a
reaction medium containing 10 mM KH2PO4, pH 7.8, 2 mM EDTA, 50
mM malate, and 0.1% Triton X-100. Enzyme activity was measured at
37°C. Protein concentration was determined by the Bradford assay. Re-
agents were of the highest grade commercially available from Sigma-Al-
drich (France).
Measurement of ADP:ATP ratio. The ADP:ATP ratio was deter-
mined by a luminometric method, using an ApoSENSOR ratio assay kit
(BioVision, Mountain View, CA) according to the manufacturer’s in-
structions. The background-subtracted luminescence values (relative
light units) were normalized to the total protein in each sample. The
results of five independent experiments are reported.
Immunohistochemistry. Tissues were processed using standard meth-
ods. Immunochemistry was performed using Dako EnVisionSystem per-
oxidase (DAB; Dako Corporation, Carpinteria, CA) according to the manu-
facturer’s instructions.
Statistics. Unless stated otherwise, data are presented as means stan-
dard deviations (SD) and are representative of at least three independent
experiments. Statistical significance was calculated using Student’s t test.
RESULTS
Fumarase deficiency protects cells from apoptotic death. The
response to apoptotic stimuli was studied in fumarase-defective
human fibroblasts and renal cells (Fig. 1). FH-defective fibroblasts
had been derived previously from the skin of patients suffering
from fumaric aciduria (2). A mutant FH protein is expressed in
these cells (Fig. 1A) andhas severely reduced enzymatic activity (2,
34). FH-defective human renal cells were generated by expressing
FH-specific shRNAbymeans of an LV in either RPTEC in primary
culture (Fig. 1C) or HK-2 cells (Fig. 1E), which are RPTEC im-
mortalized by E6/E7 expression (49). In both RPTEC and HK-2
cells, the LV allowed the random integration and expression of
shRNAs in the majority of cells and thus effected a stable and
long-term down modulation of FH (Fig. 1C and E). Fumarase
knockdown resulted in reduced enzymatic activity, down to a re-
sidual activity of 7% of that measured in wild-type cells and com-
parable to that measured in FH-defective human fibroblasts,
which carry a homozygous FH deletion (34). In all experiments
where FH-specific interfering RNA was used, we utilized cells
transduced with an LV carrying a scrambled shRNA sequence as a
control. In addition, in FH-defective cells, FH activity was rescued
(Fig. 1A and E) by the stable expression, driven by LV, of a human
FH cDNA carrying eight silentmutations which rendered the cor-
responding mRNA unaffected by interference.
Survival of all FH-defective cells was tested after treatmentwith
different stimuli inducing cell death. It is noteworthy that gene
silencing driven by LV allows the study of bulk unselected cell
populations, on the one hand, but on the other hand results in
levels of FH silencing that vary from cell to cell depending on the
number of integrated shRNA copies. Furthermore, cell synchro-
nization was avoided because it involves cell exposure to a low
serum concentration.Nevertheless, it was possible to demonstrate
that human cells in primary cultures were protected from death
when FH was knocked down (Fig. 1). FH deficiency resulted in
protection from death of both FH-defective fibroblasts (Fig. 1B)
and renal cells (Fig. 1D and F). Rescue of wild-type FH expression
reversed this cell protection from death.
Next, we investigated whether FH-defective cells were pro-
tected from cell death mediated by apoptosis, as resistance to
apoptosis is a fundamental feature of cancer cells which allows
cells to accumulate multiple genetic defects. Figure 1G and H
show that FH deficiency impacts an apoptotic program, as an-
nexin V binding to the plasma membrane was not followed by
consistent intracellular caspase-3 cleavage and cell permeabiliza-
tion to propidium iodide.
HIF is stabilized in fumarase-defective cells, but protection
from apoptosis is a HIF-independent mechanism. It was dem-
AMPK Protects FH-Defective Cells from Apoptosis
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FIG 1 Fumarase-defective cells are protected from apoptosis. (A) FH-defective fibroblasts (FH minus) express an FH gene carrying homozygous missense
mutations. In the same cells, transduction with a wild-type FH cDNA rescued the activity (FH rescue). Control fibroblasts are from a healthy individual. The blot
was reprobed with a monoclonal antivinculin antibody to show equal loading. (B) FH-defective fibroblasts (FH minus) are protected from death induced by
exposure toH2O2 andCDDP (1mMand 20M, respectively) for 48 h, towhich normal fibroblasts (control) and rescued fibroblasts aremore susceptible. In this
and the following apoptosis functional assays, healthy and treated cells were incubated with both annexin and propidium iodide, and cell viability was
measured as the percentage of propidium iodide-negative cells. *, P 	 0.003. (C) Decreased expression of the FH protein in primary cultured RPTEC
transduced with a human FH-specific shRNA (FH shRNA). (D) Untransduced RPTEC are more susceptible to CDDP (20 M for 48 h) than FH-defective
RPTEC (FH shRNA). Cell viability was measured as described for panel B. *, P	 0.006. (E) Suppression of Fh protein expression in HK-2 cells transduced
with FH-specific shRNA (FH shRNA). FH protein did not decrease in HK-2 cells transduced with a control shRNA. In FH-defective cells, FH expression
was recovered after cell transduction with an shRNA-resistant FH cDNA (FH rescue). (F) FH knockdown in HK-2 cells resulted in cell protection from
treatment with cisplatin (20 M CDDP) and staurosporine (2.5 M) for 48 h and from serum withdrawal for 7 days. Conversely, these treatments
similarly killed untransduced cells and cells transduced with a control shRNA. In FH-defective cells, FH reexpression rescued cell susceptibility to cell
death. Cell viability was measured as described for panel B. *, P 0.05. (G) FH knockdown protected HK-2 cells from apoptosis, as they accumulated less
activated caspase-3 after treatment with 20 MCDDP for 48 h. (H) Time course of the apoptotic response of FH-defective cells to treatment with 20 M
CDDP. Cells which were in the early phase of apoptosis displayed a loss of plasma membrane asymmetry and were stained only with APC-labeled annexin
V (AnV), which measures exposure of phosphatidylserine at the cell surface. Cells in the intermediate and late phases of apoptosis presented large plasma
and nuclear membrane ruptures, which were revealed by simultaneous annexin V binding and propidium iodide (PI) staining.
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FIG 2 HIF-1 and HIF-2 are stabilized in FH-defective cells but are dispensable for cell protection from apoptosis. (A) Knocking down FH by
interfering RNA (FH shRNA) in HK-2 cells resulted in nuclear (nuc.) but not cytoplasmic (cyt.) accumulation of HIF-1 and HIF-2 under normoxic
conditions, comparable to that obtained by treating cells with 200 M cobalt chloride (CoCl2) for 24 h. To study the role of HIF-1, the latter was down
modulated by stable expression of a specific interfering shRNA (HIF-1 shRNA). The same Western blot was reprobed with a monoclonal GAPDH
antibody to show equal loading. (B) HIF-1 down modulation by HIF-1 shRNA was also detectable at the mRNA level, as measured by quantitative
real-time PCR. The mean fold change of HIF-1 gene expression was calculated using the following formula: CT
 [(CT HIF-1  CT cyclophilin A for FH
shRNA cells, HIF-1 shRNA cells, or HIF-1 shRNA and FH shRNA cells) (CT HIF-1CT cyclophilin A for FH shRNA cells)]. (C) FH-defective HK-2 cells
remained viable after treatment with 20 M CDDP for 72 h and were not affected by the simultaneous down modulation of HIF-1. Also, the response
of FH-proficient HK-2 cells was not affected by HIF-1 knockdown. (D) Mouse Fh1 was knocked down by means of stable expression of a specific
interfering RNA (Fh shRNA) in the Hif-1/Arnt-proficient mouse hepatoma Hepa-1C1c7 cell line; its mutant derivative subclone c4, which lacks a
functional Hif-1/Arnt protein; and a revertant clone of the c4 subclone, vT{2} cells, in which the functionality of the Arnt protein is restored by cDNA
reexpression. Western blots were probed with a polyclonal anti-human FH antibody, which also labels the mouse protein, and with a monoclonal
anti-mouse GAPDH antibody to show equal loading. (E) The aforementioned cells were protected from treatment with 20 M CDDP for 72 h when FH
was knocked down, irrespective of the functionality of Hif-1/Arnt. (F) FH-defective HK-2 cells accumulated ROS even in the absence of added hydrogen
peroxide (H2O2). ROS-positive cells were measured as the percentage of cells which accumulated the red fluorescent dye MitoSOX. (G to I) FH-defective
HK-2 cells remained similarly viable when treated with 20 M CDDP for 48 h in the presence of the indicated concentrations of either N-acetylcysteine
(NAC) (G), sodium pyruvate (H), or the LDH inhibitor oxamate (I) or in the presence of vehicles used to dissolve the compounds ().
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onstrated previously that in FH-defective cells and MCUL/
HLRCC tumors (42, 44), the HIF- subunits are stabilized and
HIF-dependent transcription is induced. Using immunofluores-
cence, HIF-1was found to have accumulated in the nuclei of the
above-mentioned FH-defective human fibroblasts (P. Rustin, un-
published data). Accordingly, FH knockdown led to HIF-1 and
HIF-2 nuclear accumulation inHK-2 cells under normoxic con-
ditions (Fig. 2A).
Therefore, we first hypothesized that the survival advantage
conferred by FH deficiency depends on HIF-1 subunit stabiliza-
tion. To ascertain whether this was correct, FH-defective and FH-
proficient HK-2 cells were transduced with LV carrying shRNAs
specific for the human HIF-1 sequence. HIF-1mRNA was de-
creased consistently in both FH-proficient and FH-defective cells
(Fig. 2B), and the corresponding protein was down modulated
concordantly (Fig. 2A). The apoptotic response was assayed in
cells in which either FH or HIF-1 alone or both FH and HIF-1
were knocked down. Figure 2C shows evidence that FH-defective
cells and FH-defective cells inwhichHIF-1was downmodulated
were similarly protected from death. The same results were ob-
tained after silencing of HIF-1 in cells by use of an LV carrying
another HIF-1-specific shRNA sequence (data not shown). This
is also in agreement with our finding that Fh1 suppression makes
Hif-1 knockout mouse embryo fibroblasts as resistant to apop-
tosis as wild-type MEFs (6). These data show that the protection
from apoptosis due to FH knockdown is independent of HIF-1.
Alternatively, HIF-2 might be responsible for the apoptotic
protection observed in FH-defective cells, as HIF-1 and HIF-2
stimulate the expression of overlapping as well as unique tran-
scriptional targets and their induction can have distinct biological
effects (13). The HIF-2 protein, as well as HIF-1, dimerizes
with HIF-1, also known as an aryl hydrocarbon receptor nuclear
translocator (ARNT), to bind DNA and to activate transcription.
In order to determine the role, if any, of the HIF-2 pathway in
FH-defective cells, we usedmouse cells lacking functional Hif-1/
Arnt, which were transduced with LV to stably express a murine
Fh1-specific shRNA (Fig. 2D). Figure 2E shows that all the Fh1-
defective cells were protected from death, regardless of the func-
tionality of the HIF-2 pathway, thus demonstrating that HIF-2
stabilization does not contribute to cell survival of FH-defective
nontransformed cells. This finding further ruled out the role of
HIF-1 in the survival of FH-defective cells.
It has been reported (55) that FH loss might result in the gen-
eration of ROS. In agreement, we found a 5-fold increase in ROS
levels in FH-defective HK-2 cells (Fig. 2F). To determine whether
the increase in ROS contributes to cell protection from apoptosis,
the response of FH-defective HK-2 cells to apoptotic stimuli was
assayed in cells grown in the presence of eitherN-acetylcysteine or
pyruvate, both of which are antioxidants. Protection from apop-
tosis was unaffected (Fig. 2G and H). In addition, it has been
shown that when FH is lost in transformed cells, HIF stabilization
results in increased expression of LDH, which can mediate cell
FIG 3 Survey of kinases activated in FH-defective cells. Phosphorylation of either kinase substrates or kinases themselves was studied as a surrogate marker of
kinase activation, using the Bio-Plex phosphoprotein assay and Western blot analysis. HK-2 cells were exposed to 40 MCDDP for the indicated times, which
in most instances is known to activate survival kinases. (A) Phosphorylation was measured using the Bio-Plex phosphoprotein assay. The change in the
phosphorylation level of each protein in FH-defective versus FH-proficient (untransduced) cells is shown. Bars show SD. (B) As described for panel A,
phosphorylation of the same proteins wasmeasured after CDDP treatment and is shown as the ratio of levels in treated versus untreated cells in FH-defective and
FH-proficient (untransduced) cells. In panels C to E, Western blots of the phosphorylated forms of the indicated kinases are shown versus total protein
expression. (C) PKA was similarly and modestly affected by CDDP in FH-defective and FH-proficient (untransduced) cells. (D) p70S6K was similarly activated
by CDDP treatment in FH-defective and FH-proficient (untransduced) cells. (E) Increased phosphorylation of p38 MAPK was detected after 24 h of treatment
with CDDP in both FH-defective and FH-proficient (untransduced) cells and was associated with decreased protein expression.
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protection from apoptosis (58). Thus, apoptosis was assayed in
cells treatedwith the LDH inhibitor oxamate. Figure 2I shows that
LDH inhibition did not hamper the survival of FH-defective cells.
Taken together, these data show that protection from apopto-
sis of FH-defective nontransformed kidney cells relies on a HIF-
independent mechanism.
Fumarase knockdown protects cells from apoptosis by ac-
tivating AMPK. Next, we investigated the molecular mecha-
nism(s) underlying the survival advantage conferred by FH
knockdown. We considered whether survival kinases were ac-
tivated in response to apoptotic stimuli in FH-defective HK-2
cells. We carried out a survey with antibodies directed against
FIG 4 AMPK is constitutively activated in FH-defective normal kidney cells. (A) AKT was less phosphorylated at Ser473, indicating AKT activation, in
FH-defective (FH shRNA) HK-2 cells than in control cells (untransduced). Phosphorylation was slightly increased after cell treatment with 40 MCDDP. (B)
In FH-defective (FH shRNA) HK-2 cells, AMPK was constitutively more phosphorylated at Thr172, which is marker of AMPK activation, and further activated
by CDDP treatment. Activation of AMPK is also demonstrated by the increased phosphorylation of its specific substrate, ACC, labeled by an anti-P-ACC
antibody. (C) A quantitative ELISA confirmed the increased phosphorylation of AMPK at Thr172 in FH-defective HK-2 cells compared to control cells. Results
are presented as average absorbances SD for three independent experiments. In each experiment, the absolute absorbance at 450 nm was normalized to the
protein concentration. (D) AMPK remained more phosphorylated in FH-defective HK-2 cells even when HIF-1 alone was down modulated by the specific
shRNA. (E) FH down modulation (FH shRNA versus untransduced cells) also resulted in AMPK activation in primary cultured RPTEC.
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known kinase substrates and the phosphorylated forms of a
number of candidate kinases (Fig. 3). Indeed, most kinases are
themselves activated by phosphorylation at critical residues,
and the phosphorylation status is a surrogate marker of their
activation.
The mitogen-activated protein kinase (ERK1/2), the mitogen-
activated protein kinase kinase 1 (MEK1), and the AMP-activated
kinase (AMPK)were all constitutivelymore activated in untreated
FH-defective cells than in untreated FH-proficient HK-2 cells
(Fig. 3A and 4B), while the serine/threonine protein kinase AKT/
PKB (Fig. 4A) and the ribosomal protein S6 kinase p90RSK (Fig.
3A) were less phosphorylated at residues marking activation. Cell
treatment with an apoptotic stimulus did not increase the phos-
phorylation of MEK1 and ERK1/2 in FH-defective cells (Fig. 3B),
while it slightly activated AKT and further increased AMPK acti-
vation (Fig. 4A, B, and C).
AMPK activation was also detected in FH-defective primary
cultured kidney cells (Fig. 4E). Moreover, AMPKwas activated by
FH suppression in HK-2 cells in which HIF-1 was down modu-
lated (Fig. 4D). This showed that HIF stabilization and AMPK
activation were unrelated consequences of FH suppression.
We focused further analyses on AMPK, which is phosphory-
lated in FH-defective cells. Additionally, functional assays con-
firmed that AMPK activation is able to protect kidney cells from
apoptosis. Activation was obtained using the AMPK activators
AICAR, metformin, and A769662 (Fig. 5A and B). In the mirror
experiment, the consistent simultaneous knockdown of both the
1 and 2 subunits of AMPK in both FH-depleted and control
HK-2 cells resulted in cell death, irrespective of FH activity (data
not shown).
To further substantiate the prosurvival role of AMPK in FH-de-
fective cells, Fh1 was suppressed in Ampk 1/2 double-knockout
(Ampk/)MEFs (29) (Fig. 5C).As shown inFig. 5D, cisplatin treat-
mentaffectedcontrolMEFsandAmpk/MEFs.However,Fh1sup-
pression in controlwild-typeMEFs resulted inAmpk activation (Fig.
5C)andprotected them,butnot theAmpk/MEFs, fromapoptosis
(Fig. 5D), demonstrating the key role of Ampk inmediating the pro-
tective role of Fh1 suppression.
Activated kinases regulate cell survival at different levels. Be-
cause we had demonstrated (Fig. 1) that caspase-3 cleavage was
reduced in FH-defective cells treated with an apoptotic stimulus,
we investigated the known pathways regulating apoptosis. For
HK-2 cells, we ruled out the role of p53, as these cells are immor-
talized by overexpression of the human papillomavirus E6/E7 on-
coprotein, which downregulates p53 (49). We then studiedmem-
bers of the BCL2 family, a group of homologous proteins with
FIG 5 AMPK protects cells from apoptotic death and is necessary for the apoptosis protectionmediated by FH suppression. (A) The treatment of FH-proficient
HK-2 cells with AICAR (1 mM for 48 h), metformin (2 mM for 48 h), and A769662 (1 M for 48 h), which are cell-permeating AMPK activators, resulted in
increased AMPK phosphorylation at Thr172. (B) The apoptotic response to 20MCDDP for 48 h was analyzed, as in Fig. 1, in FH-proficient HK-2 cells. Either
AICAR, metformin, or A769662 protected cells from apoptosis. Significance was calculated by comparing each triplicate of samples treated with an AMPK
activator and CDDP to a triplicate of cells treated with CDDP alone. *, P	 0.01. (C) fh1 suppression in control MEFs resulted in Ampk activation, which could
not be seen in Ampk/MEFs. (D) CDDP treatment (40M for 48 h) affected controlMEFs and Ampk/MEFs. Fh1 suppression protected controlMEFs but
not Ampk/MEFs against CDDP.
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either pro- or antiapoptotic effects (3, 59), which initiate cell death
at themitochondrial level.We evaluated changes in the expression
and phosphorylation of the following proteins in FH-defective
HK-2 cells: the antiapoptotic proteins BCL2, BCL-XL, and MCL1
and the proapoptotic proteins BAX, BAK, BAD, BIK/NBK, BIM/
BOD, and BMF. Some data are shown in Fig. 6. We found that
members of the BCL2 family are affected by FH suppression. The
antiapoptotic MCL-1 and BCL-XL proteins were increased rather
than decreased by the apoptotic stimulus (Fig. 6A). Despite
AMPK activation, we did not find increased expression of BIM
(data not shown), which has been associatedwith excitotoxicity in
neurons (4). BMF, described as the proapoptotic effector of
AMPK activation in pancreatic beta cells (26), was even slightly
upregulated by CDDP (Fig. 6B). Quantitative PCR analysis
showed that MCL1 and BMF regulation occurred at the protein
level (data not shown).
We observed that BAD, which is a proapoptotic protein, was
regulated very differently in FH-defective cells and control cells
(Fig. 6D): BAD was constitutively more phosphorylated and was
not affected by an apoptotic stimulus in FH-deficient cells. A con-
nection between AMPK activation and BAD phosphorylation has
already been reported (9, 25, 45). In agreement, treatment of kid-
ney cells with the AMPK activator AICAR resulted in increased
BAD phosphorylation (Fig. 6E).
It is known that phosphorylation functionally impairs the pro-
apoptotic activity of BAD. Thus, we investigated whether loss of
BAD function impacts kidney cell survival. We silenced BAD ex-
pression in both FH-proficient and FH-defective HK-2 cells by
using a human BAD-specific shRNA and the relevant control
shRNA (50). Figure 7 shows that the resulting decrease in BAD
expression made FH-proficient and FH-defective cells equally
protected from apoptotic death.
Altogether, these data show, surprisingly, that the energy sen-
sor AMPK,which is inactivated in several tumor types, is activated
rather than inhibited after the loss of a mitochondrial tumor sup-
pressor gene. AMPK activation affects members of the BCL2 fam-
ily, which regulate the apoptosis machinery at the mitochondrial
level.
AMPK is activated by fumarate accumulation in fumarase-
defective cells. To assess whether AMPK might play a role in tu-
morigenesis initiated by loss of the FH tumor suppressor gene, we
examined renal cysts from mice with targeted deletion of the Fh1
gene (44). We observed an accumulation of the phosphorylated
forms of AMPK and its specific substrate, acetyl coenzyme A car-
boxylase (ACC), in the epithelium lining the cysts (Fig. 8A, B, D,
and E), which we have previously shown to be Fh1-null (44).
Phospho-AMPK was also detected in 5/6 kidney cancers from
HLRCC patients (Fig. 8G, H, J, and K).
To investigate the mechanism of AMPK activation after FH
suppression, we measured the ADP:ATP ratio, as a relative loss of
ATP triggers AMPK activation. As expected, ATP production was
lower in FH-defective kidney cells than in control cells (Fig. 9A).
However, reversion of the energetic impairment did not abolish
AMPK phosphorylation. This was shown by studying MEFs iso-
lated from mice bearing a conditionally inactivated Fh1 allele
(Fh1/MEFs). In Fh1/MEFs, Ampk was activated (constitu-
FIG 6 Study of Bcl-2 family members in FH-defective cells. Pro- and antiapoptotic activities of Bcl-2 family members are regulated at either the transcriptional
or posttranscriptional level. Thus, expression (A and B) and phosphorylation (C and D) of a number of them were studied by Western blot analysis of
FH-defective (FH shRNA) and FH-proficient (untransduced) HK-2 cells before and after treatment with 40 M CDDP for the indicated times. (A) After
treatment, both the prosurvival proteinsMCL-1 and BCL-XL were less decreased in FH-defective than in FH-proficient cells. (B) Expression of the proapoptotic
proteins BMF and BAX was similarly induced by CDDP. (C) BCL-2 was comparably phosphorylated after treatment with CDDP in FH-defective and FH-
proficient cells. (D) Conversely, the phosphorylation of BAD was higher in FH-defective HK-2 cells than in FH-proficient cells and was not modified by CDDP
treatment. All blots were reprobed with either antibody against the total protein or a monoclonal vinculin antibody to show equal loading. (E) Treatment of
FH-proficient HK-2 cells (untransduced) with AICAR, a cell-permeating AMPK activator, resulted in increased AMPK and BAD phosphorylation.
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tively phosphorylated) (Fig. 9B and C). In Fh1/MEFs after the
reexpression of a full-length human FH cDNA (39), fumarate ac-
cumulation was fully corrected and oxygen consumption and
ATP levels were restored to normal (39). In these cells, Ampk
activation was greatly diminished as a consequence (Fig. 9B). We
then examined the effects of expressing an FH cDNA that lacks the
mitochondrial targeting sequence (FHMTS) and is thus con-
fined to the cytosol (Fig. 9B). Expression of FHMTS does not
restore respiration andATP loss but still lowers fumarate accumu-
lation (39). In these cells, activated Ampk was still greatly dimin-
ished. Glucose supplementation of the culturemedium of Fh1/
MEFs did not lower AMPK activation; this was further activated,
as expected, in cells growing in medium with a low concentration
of glucose (Fig. 9D). These data suggested that fumarate accumu-
lation, not defective respiration and subsequent energy deficiency,
was responsible for AMPK activation. The data also confirmed
that AMPK activation was not due to a change in the ADP:ATP
ratio, as evidenced in cells where only the cytosolic Fh1 expression
was restored (39; data not shown).
Fumarate is a potent inhibitor of some 2-oxoglutarate-depen-
dent oxygenases (43). Therefore, we questioned whether AMPK
activation in FH-deficient cells may be due to fumarate-mediated
competitive inhibition of an oxygenase. To address this, we
treated Fh1/MEFs (Fig. 9B) with cell-permeating 2-oxogluta-
rate. This has been shown previously to restore impaired HIF hy-
droxylation (36), including that in Fh1-deficent MEFs (39). Re-
markably, AMPK activation was unaffected after treatment with
2-oxoglutarate and therefore is probably independent of oxygen-
ase activity (Fig. 9B). These data suggest that AMPK activation in
fumarase-defective cells is due to the accumulation of fumarate
and are therefore indicative of a mechanism specific to fumarase
deficiency and not due to the energetic impairment.
Another potential mechanism linking fumarate with AMPK
activation is the involvement of G-protein-coupled receptors
(GPCRs) (22). Among the hundreds of GPCRs encoded in the
human genome (10), some have been identified which are acti-
vated by TCA cycle intermediates (18), including the succinate
receptor (46). Since fumarate and succinate accumulate in FH-
defective cells (42), we questionedwhether fumarate, succinate, or
both could activate AMPK through a receptor-mediated mecha-
nism. Cells were exposed to monoethyl fumarate, diethylsucci-
nate, and exogenous succinate, with the latter being non-cell per-
meating. Both cell-permeating and -nonpermeating metabolites
elicited ERK1/2 and AMPK activation in a 5- to 15-min time
course and in temporal order (Fig. 9E and F).
In summary, these data show that the activation of AMPK ob-
served in fumarase-defective cells is due to the accumulation of
fumarate, and possibly also succinate, but not to energetic impair-
ment or altered metabolic signaling. The kinetics of ERK1/2 and
AMPK activation after acute exposure of kidney cells to TCAme-
tabolites suggests that kinase activation might be due to GPCR
activation.
DISCUSSION
Here we show that by avoiding death by apoptosis, cells defective
in FHdisplay a survival advantagewhichmight contribute directly
to tumorigenesis and that this property relies on activation of the
energy sensor AMPK and is independent of the HIF pathway.
In agreement with previous reports (42, 51), we found that FH
loss in normal kidney cells leads to both HIF-1 and HIF-2 ac-
cumulation but that these factors are not required for protection
from apoptosis in this context. These data confirm our previous
observation that Fh1 suppression makes Hif-1 knockout MEFs
as resistant to apoptosis as wild-type MEFs (6). Moreover, a
mouse model recently provided genetic evidence that Fh1-associ-
ated cyst formation is Hif independent (1). It is likely, however,
FIG 7 BAD is vital for protection of renal cells from apoptosis. (A) BAD
expression was knocked down in HK-2 cells by stably transducing cells with a
BAD-specific shRNA. Cells were also transduced to express the other indicated
shRNA (FH specific or FH control) and with the FH cDNA (FH rescue). As a
control for BAD-specific shRNA, cells were transduced with a scrambled BAD
shRNA. (B) HK-2 cells in which either FH or BAD was down modulated
remained similarly viable after treatment with 20MCDDP for 72 h. (C) Both
BAD and FH knockdown protected HK-2 cells from an apoptotic death, as
they similarly accumulated less activated caspase-3 after treatmentwith 20M
CDDP for 48 h.
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that HIF-1 and HIF-2 contribute to FH-defective cell survival
in vivo, as they regulate the expression of antiapoptotic and pro-
apoptotic genes and, in several instances, protect cells from death.
We found that AMPK is phosphorylated at threonine 172, i.e.,
activated, in normal cells in which FH activity is downregulated
and the cells are protected from death.Moreover, FH suppression
fails to protect normal kidney cells and fibroblasts devoid of
AMPK activity. In mirror experiments, AMPK activation in nor-
mal kidney cells resulted in cell protection from death. Since
AMPK was activated in these cells by AICAR, metformin, and
A769662, which work through different mechanisms (17), we are
confident that the results are indeed due to AMPK activation.
Interestingly, we found that the phosphorylation (an indicator of
activation) of AKT is reduced in FH-defective cells; this might
contribute to AMPK activation, as it has been demonstrated that
AKT inhibits AMPK activation and the associated phosphoryla-
tion at threonine 172 by phosphorylating the inhibitory threonine
485 of AMPK (38).
AMPK plays an antiapoptotic role under other physiological
and pathological conditions: AMPK activation protects neurons
from metabolic insults (28) and myocardial cells from injuries,
both in vitro and in vivo (40, 48). In several instances, BCL2 family
proteins have been implicated in protection mediated by AMPK
activation (4, 9, 25, 26). We report here that among them, BAD is
constitutively phosphorylated in FH-defective cells. Phosphoryla-
tion of BAD impairs its antiapoptotic role at the mitochondrial
level, and several kinases which signal cell survival are known to
regulate BAD phosphorylation (5). Also, activated AMPK has al-
ready been reported to protect cells by increasing the level of phos-
phorylated BAD, likely indirectly (9, 25, 45). We also found inhi-
bitionof c-JunN-terminal kinase (JNK) inFH-defective cells (Fig. 3);
this is interesting because it is known that BAD phosphorylation is
also regulated by AMPK-dependent JNK inhibition (45).
Activation of AMPK in FH-defective cells is independent of
HIF stabilization and is not due to ATP depletion, which we
found in FH-defective cells both here and elsewhere (39), but
to fumarate accumulation. However, it is not due to the meta-
bolic signaling triggered by fumarate accumulation, which
FIG 8 AMPK is activated inmurine cysts and human papillary kidney tumors which have lost FH activity. (A and B) Phosphorylated, i.e., activated, P-Ampkwas
detected in epithelial cells liningmouse renal cysts frommice with an fh1 targeted deletion, using anti-P-Ampk antibodies for immunohistochemistry. (C) In the
mouse kidney, P-Ampk was detected, as expected, mainly in collecting ducts. (D to F) The phosphorylated form of ACC, a known Ampk substrate, was similarly
distributed in bothmouse renal cysts (D and E) and themouse control kidney (F). The phosphorylated form of AMPKwas detected in type II papillary renal cell
carcinomas from HLRCC patients (G, H, J, and K) and in the collecting ducts of normal renal tissues (I and L). Bars, 50 m (all panels but B and E) or 100 m
(B and E).
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might lead to inhibition of the ferrous ion and 2-oxoglutarate-
dependent oxygenases (33). This allowed unveiling of a new
mechanism which might contribute to tumorigenesis due to
FH tumor suppressor loss.
Succinate accumulates in FH-defective cells, in a manner sim-
ilar to that of fumarate (42). We found that both fumarate and
succinate trigger EKR1/2 and AMPK activation, with kinetics
compatible with a receptor-mediated mechanism. This is not un-
expected, as TCA metabolites can be excreted (30) and might ac-
tivate GPCRs (18). Among the hundreds of GPCRs encoded in the
human genome (10), a succinate receptor was found that is ex-
pressed distinctively in the kidney (46). Also, it has been shown
that the succinate receptor activates ERK1/2 in kidney cells (47)
and that a number of GPCRs might also activate AMPK (22),
FIG 9 AMPK activation is due to fumarate accumulation in FH-defective cells. (A) The ADP:ATP ratio was decreased in FH-defective HK-2 cells. (B) In MEFs
propagated from Fh1 knockout mice (Fh1/MEFs), Ampk was constitutively phosphorylated and Hif-1 was increased by stabilization. The expression of a
V5-tagged cDNA encoding wild-type FH (FH-V5) abrogated Hif-1 stabilization and slightly reduced Ampk phosphorylation. The expression of the same
V5-tagged cDNA devoid of the mitochondrial targeting sequence (FHMTS-V5) similarly abrogated Hif-1 stabilization and more strongly reduced Ampk
phosphorylation. The treatment of Fh1/MEFswith 2-oxoglutarate (2OG), which reverts a blockade of 2-oxoglutarate-dependent oxygenases (2mM for 2 and
8 h), abrogated Hif-1 stabilization but did not affect Ampk phosphorylation. (C) Quantitative ELISA confirmed that Fh1/ MEFs displayed an increased
phosphorylation of Ampk at Thr172 compared to wild-type MEFs (control). Results are presented as average absorbances  SD for three independent
experiments. In each experiment, the absolute absorbance at 450 nmwas normalized to the protein concentration. (D) In Fh1-defectiveMEFs, Ampk is activated
and activation is not suppressed by glucose supplementation of the medium to high concentrations (25 to 50 mM). Low concentrations of glucose (3 to 6 mM)
activated Ampk in both control and Fh1-defective MEFs. (E) Treatment of FH-proficient HK-2 cells with monoethylfumarate (500M) for the indicated times
resulted in increased ERK1/2 and AMPK phosphorylation. (F) Similarly, treatment of FH-proficient HK-2 cells with either succinate (200 M) or diethyl
succinate (200 M) resulted in more ERK1/2 phosphorylation, i.e., activation, than that in untreated cells (NT); in temporal order, AMPK was phosphorylated
to a level comparable to that obtained by treating cells with AICAR.
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independent of ERK1/2 activation. Intriguingly, each GPCR has a
tissue-specific distribution (46), which might contribute to the
understanding of tissue-specific tumorigenesis due to FHand suc-
cinate dehydrogenase (SDH)defects, which similarly stabilizeHIF
in all tissues (14).
AMPK is a highly conserved sensor of cellular energy status
(16, 53) and suppresses cell growth and biosynthetic processes
through the mammalian target-of-rapamycin pathway (16). Here
we show that AMPK activation in nontransformed kidney cells,
mouse kidney cysts, and kidney cancers of HLRCC patients does
not result in inhibition of cell growth. In HK-2 cells, lack of inhi-
bition might be due to p53 inactivation. In other cells, p27 phos-
phorylation and cytoplasmic accumulation might be hypothe-
sized, as p27 might be phosphorylated by AMPK in both kidney
cells and fibroblasts (27) and phosphorylation prevents p27 from
translocating to the nucleus and inhibiting the cell cycle. The
AMPK upstream activator is the protein product of the LKB1
tumor suppressor gene (54). Oncogenic mutations might actively
dismantle the LKB1-AMPK axis (60). Such data highlight the role
of AMPK as a member of tumor-suppressive pathways. We dem-
onstrate here that, surprisingly, AMPKmight play an “oncogenic”
role in human cells. The activated formofAMPKaccumulated not
only in vitro, in FH-defective renal cells and Fh1/ MEFs, but
also in vivo, in mouse cysts of Fh1-null mice and in a number of
papillary renal cell carcinoma samples from HLRCC patients.
These data show that AMPK activation not only might be an early
and possibly transitory event in FH-driven tumorigenesis but also
might sustain cell protection from death in established cancer.
The lattermight appear in contrast to the results reported by Tong
et al. (57), who showed that AMPK was suppressed in spontane-
ously immortalized cell lines from papillary renal cell carcinomas
of HLRCC patients. They also showed three tumor samples neg-
ative for AMPK staining. Becausewe also found one negative sam-
ple, we could infer that stringent conditions might drive selection
of more aggressive cancer cells, which likely require AMPK sup-
pression to surmount accumulation of genetic defects.
These findings, besides highlighting a new mechanism for FH
loss in tumorigenesis and a novel role for AMPK in both normal
and transformed cells, are important in considering AMPK acti-
vation as a therapeutic strategy against cancer (16, 41). Targeting
AMPK is immediately feasible, as metformin is approved for the
therapy of diabetes. Preclinical (20, 21) and epidemiological (24,
31, 32) studies have prompted clinical trials (12, 15) to evaluate
the effects ofmetformin on the treatment or prevention of human
cancer. Regrettably, we show here that AMPK activation not only
might be ineffective but alsomight be harmful when tumors pres-
ent with a particular genetic profile, such as inactivation of FH,
p53, and cell cycle inhibitors or expression of AMPK. This sug-
gests that themolecular profile of every tumor should be evaluated
before reactivating treatment and reinforces the need to person-
alize each patient’s treatment on the basis of the genetic and mo-
lecular characteristics of that patient’s tumor.
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